[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"end-stage-renal-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:end-stage-renal-disease":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,63,0,25,[9,53,74,105,135,161,189,218,242,266,286,313,340,361,387,416,453,481,510,537,562,585,617,643,666],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100541211","capable-transplant-100541211",false,"NCT06326905","CAPABLE Transplant","Addressing Inactive Kidney Transplant Waitlist Status Through Adapting a Tailored Psycho-Social-Environmental Program","Inclusion Criteria:\n\n* Deceased Donor Waitlist\n* ≥18 years old\n* Community dwelling\n* Current Inactive status or active and had been inactive in the last 18 months for cardiovascular disease, frailty, obesity, social support, mental health, incomplete testing OR Active on the waitlist and low-income\n\nExclusion Criteria:\n\n* Living Donor Waitlist\n* Severe cognitive impairment\n* Inactivity expected to last \\> 3 months (eg cancer treatment)\n* \\>4 hospitalizations in the last 12 months\n* Current home nursing, physical or occupational therapy","ALL","18 Years","99 Years",{"count":21,"type":22},43,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this mixed methods study is to adapt CAPABLE as CAPABLE Transplant to accomplish two things: 1) To resolve barriers to being classified as active on the Kidney Transplant (KT) waitlist, 2) as a surgical prehabilitation intervention targeting the pre-frail\u002F frail KT waitlist population. It consists of two phases- an open label pilot and a randomized waitlist control trial, and 3) pilot test the feasibility and acceptability for CAPABLE Transplant in symptom and waitlist specific metrics amongst low-income active kidney transplant waitlist candidates.",[28,29,30,31],"Quality of Life","Depression","End Stage Renal Disease","Disability Physical",[33,34,35,36,37,38,39,30],"Activities of Daily Living","Instrumental Activities of Daily Living","Physical Function","Executive Function","Home","Intervention","Kidney Transplant","RECRUITING","2026-06-30",{"date":43,"type":44},"2026-07-02","ACTUAL",{"date":46,"type":44},"2025-01-25",{"date":48,"type":22},"2026-07-01",{"name":50,"class":51},"Johns Hopkins University","OTHER",1,{"id":54,"slug":55,"hasResults":12,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100644449","bicmag-study---improving-mineral-buffering-capacity-in-dialysis-patients-100644449","NCT07663279","BicMag Study - Improving Mineral Buffering Capacity in Dialysis Patients","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Prevalent patients (≥ 3 months) treated with thrice weekly hemodialysis or hemodiafiltration\n* Dialysate calcium of 1.25 mmol\u002Fl\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Currently participating in another investigational device or drug study or non-interventional study\n* Dialysate calcium other than 1.25 mmol\u002Fl\n* Parathyroidectomy planned during the study\n* Elective living-donor kidney transplant scheduled during the study period\n* Therapy with bisphosphonates within the past 12 months or denosumab within the past 6 months\n* Pregnant or nursing (lactating) women",{"count":60,"type":22},91,[25],"The BicMag study is a prospective, randomized, controlled cross-over study that aims to examine the potential additive effect of a dialysate enriched with both bicarbonate and magnesium on mineral buffering capacity in the blood of chronic hemodialysis patients.",[30],"NOT_YET_RECRUITING","2026-06-17",{"date":67,"type":44},"2026-06-23",{"date":69,"type":22},"2026-10",{"date":71,"type":22},"2029-12",{"name":73,"class":51},"Elisabethinen Hospital",{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100530107","development-and-test-of-a-communication-skills-training-for-transplant-providers---aims-2--3-100530107","NCT06182475","Development and Test of a Communication Skills Training for Transplant Providers - Aims 2 & 3","Increasing Equity in Live Donor Kidney Transplantation Through Effective Patient-Provider Communication","EPPComm","Inclusion Criteria:\n\n* (1) appear for a kidney transplant evaluation at Cooperman Barnabas Medical Center (CBMC) or Temple University Hospital (TUH)\n* (2) speak English\n* (3) be of self-reported Black or Caucasian ethnicity\n* (4) be ≥18 years of age.\n\nIncluding patients who:\n\n1. have received prior kidney transplants\n2. patients with limited English proficiency, as long as they speak with the physician via a translator\n3. patients evaluated at offsite satellite locations that are not actually at CBMC or TUHS.\n\nAll transplant nephrologists, nurses, and social workers employed at the kidney transplant programs at CBMC and TUH who are actively involved in patient evaluations for transplant will be eligible for participation in the study. Providers refusing to permit digital audio recording of the transplant consultation will be deemed ineligible.\n\nExclusion Criteria:\n\n* (1) are non-verbal or otherwise unable to converse with providers\n* (2) are already listed for kidney transplant at CBMC or TUHS or at another transplant center\n* (3) have limited English proficiency and speak directly with the physician in a language other than English.\n\nPatients having (1) received an offer to donate a kidney from a family member or friend, or (2) explicitly asked a family member or friend to consider serving as a LD will be excluded, along with any patients refusing to permit digital audio recording of the transplant consultation will also be deemed ineligible to participate.\n\nThe following special populations will be excluded: adults unable to consent, individuals who are not yet adults (infants, children, teenagers), prisoners, and individuals who do not understand English.\n\nIt is unlikely that any female patient will be pregnant while awaiting kidney transplant; however, we will not exclude pregnant women.","80 Years",{"count":84,"type":22},70,[25],"The goal of this clinical trial is to understand the communication occurring between Black and Caucasian patients and their transplant providers during transplant evaluation consultations and assess relationships between these communicative elements and patient and provider factors, patient-reported outcomes and living donor transplant outcomes - living donor referrals, evaluations, and transplants. We will use these findings to inform the development of a communication skills training for transplant providers and test the impact of the training on providers' communication about live donor kidney transplants with Black and Caucasian patients and living donor transplant outcomes.\n\nThe main questions it aims to answer are:\n\n* How does the use of the use of instrumental, relational and affective communication by patients and providers during the transplant consultation differ by patient and provider factors, patient-reported outcomes and patient ethnicity?\n* What elements of instrumental, relational and affective communication will be predictive of live donor kidney transplant (LDKT) process outcomes (LD inquiries and evaluations, and actual LDKTs)?\n\nParticipants will be asked to complete brief surveys before and after the transplant consultation and to give permission for the consultation to be audiorecorded.\n\nThis data will be used to develop a training to educate providers on the key communication factors predictive of LDKT process outcomes specific to Black and Caucasian patients, and provide guidance on their application during patient consultations. Researchers will then compare communication and patient-reported and LDKT process outcomes between trained and untrained providers to see whether the training has any effect on living donor inquiries and evaluations, and actual LDKTs.",[88,30,89],"Kidney Disease, Chronic","Kidney Replacement",[91,92,93,94],"Patient-Provider Communication","Live Donor Kideny Transplantation","Provider Training","Communication Skills Training","2026-06-10",{"date":97,"type":44},"2026-06-12",{"date":99,"type":22},"2026-09",{"date":101,"type":22},"2027-05",{"name":103,"class":51},"Temple University",2,{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":112,"sex":17,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":134},"100619716","phase-1-a-clinical-trial-of-mk-2828-in-people-with-kidney-disease-mk-2828-006-100619716","NCT07348237","A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)","An Open-Label, Single-Dose Clinical Study to Evaluate the Pharmacokinetics of MK-2828 in Participants With Renal Impairment","The main inclusion criteria include but are not limited to the following:\n\n* Is in generally good health, with the exception of renal impairment participants. Participants with stable, chronic medical or psychiatric conditions may be included at the discretion of the investigator and the Sponsor.\n\nSevere Renal Impairment Participants:\n\n* Has an estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin), but is not on hemodialysis (HD)\n\nESRD on HD Participants:\n\n* Has ESRD maintained on stable outpatient regimen of intermittent high-flux HD at a healthcare center for \\> 3 months prior to study entry\n\nThe main exclusion criteria include but are not limited to the following:\n\nRenal Impairment Participants:\n\n* History of any illness, other than renal impairment, that, in the opinion of the investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study.\n\nHealthy Matched Control Participants:\n\n* History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases. Participants with a remote history of uncomplicated medical events (eg, uncomplicated kidney stones, as defined as spontaneous passage and no recurrence in the last 5 years, or childhood asthma) may be enrolled in the study at the discretion of the investigator.",true,"24 Years","85 Years",{"count":116,"type":22},24,[118],"PHASE1","The goal of this trial is to measure what happens to 1 or 2 doses of MK-2828 in a person's body over time (pharmacokinetic or PK trial). Researchers want to learn if the PK of people with certain types of kidney disease is similar to the PK of healthy people.",[121,122,123],"Chronic Kidney Failure","End-Stage Renal Disease","Renal Impairment","2026-06-01",{"date":126,"type":44},"2026-06-02",{"date":128,"type":44},"2026-03-02",{"date":130,"type":22},"2026-07-20",{"name":132,"class":133},"Merck Sharp & Dohme LLC","INDUSTRY",3,{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":143,"targetDuration":145,"studyType":146,"phases":4,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":160},"100548582","preserve-hd-observational-study-of-the-merit-hero-graft-and-super-hero-in-patients-on-hemodialysis-100548582","NCT06422871","PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis","PReSeRVE-HD: PRospective, Multicenter, Observational Study of the Merit HeRO® Graft and Super HeRO® EValuated in End-Stage Renal Disease Patients on HemoDialysis","PReSeRVE-HD","Key Inclusion Criteria:\n\n* Subject provides written informed consent\n* Subject is ≥ 18 years\n* Subject is end-stage renal disease patient on hemodialysis.\n* Subject is treated with HeRO Graft or Super HeRO System in accordance with device instructions for use (IFU)\n\nKey Exclusion Criteria:\n\n* Subject has a previously placed HeRO or Super HeRO device that is undergoing revision or replacement\n* Subject has a topical or subcutaneous infection associated with the implantation site\n* Subject has known or suspected systemic infection, bacteremia or septicemia",{"count":144,"type":22},100,"2 Years","OBSERVATIONAL","The goal of this observational study is to increase the understanding of the safety and performance of Merit Medical's HeRO Graft System (HeRO) and Super HeRO Adaptor and Support Seal System (Super HeRO) devices. This study includes adults that are being treated with one of these devices as part of their regular medical care for maintaining long-term dialysis access when all other dialysis access options have failed. If participants in the study are not seen for a standard of care clinic visit during the 4 visit timepoints over 2 years, the participant will be followed by phone to check their current health and dialysis status.",[30,149],"Hemodialysis Access Failure",[151],"HeRO","2026-05-28",{"date":124,"type":44},{"date":155,"type":44},"2025-07-28",{"date":157,"type":22},"2028-12-28",{"name":159,"class":133},"Merit Medical Systems, Inc.",7,{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":23,"phases":171,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":188},"100351976","phase-4-the-danish-warfarin-dialysis-study---safety-and-efficacy-of-warfarin-in-patients-with-atrial-fibrillation-on-dialysis-100351976","NCT03862859","The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis","The Danish Warfarin-Dialysis Study: Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis - A Nationwide Parallel-group Open Randomized Clinical Trial","DANWARD","Inclusion Criteria:\n\n* Patients ≥18 years on chronic dialysis due to end-stage renal disease\n* Non-valvular paroxysmal, persistent, or permanent atrial fibrillation OR non-treated (for \\>2 months) prevalent paroxysmal, persistent or permanent atrial fibrillation as documented by an electrocardiogram or an episode of ≥30 seconds on Holter monitor, or episodes ≥ 6 minutes on event recorders or any other recording device.\n* Competence to understand the study rationale, including potential risks and benefits associated with treatment, necessary for written informed consent.\n\nExclusion Criteria:\n\n* CHA2DS2-VASc Score ≤1\n* Other indications for oral anticoagulation treatment (pulmonary embolism \\\u003C 6 months, deep vein thrombosis \\\u003C3 months, mechanical heart valve prosthesis) irrespective of whether treatment is implemented\n* Ongoing dual antiplatelet treatment\n* Malignancy (with exception of non-melanoma skin cancer) with recent \\\u003C 1 year, ongoing, or planned curative, or palliative chemo- , radiation-, and\u002For scheduled surgical therapy\n* Endoscopy with gastrointestinal ulcer \\\u003C1 month\n* Esophageal varices\n* Autoimmune og genetic coagulation disorders\n* Congenital alactasia, Lapp Lactase deficiency or glucose-galactose malabsorption\n* Pending spinal tap\n* Cerebrovascular malformations\n* Arterial aneurysms\n* Ulcers or wounds (Wagner grad \\>1)\n* Bacterial endocarditis \\\u003C 3 months\n* Active bleeding contraindicating anticoagulation\n* Any non-elective and\u002For non-ambulant surgery \\\u003C7 days\n* Cerebral hemorrhage \\\u003C4 weeks\n* Thrombocytopenia (platelet count \\\u003C100 × 109\u002FL) \\\u003C30 days.\n* Severe liver insufficiency (spontaneous international normalized ratio \\>1.5) \\\u003C30 days.\n* Known intolerance to warfarin\n* Use of hypericum perforatum \u002F St. John's Wort\n* Uncontrolled hypertension (repeat blood pressure \\>180\u002F110 mmhg) \\\u003C 30 days\n* Uncontrolled hyperthyroidism (thyroid-stimulating hormone \\\u003C0.1μIU\u002FmL) \\\u003C30 days\n* Pregnancy or lactation\n* Participation in other ongoing intervention trials adjudged to influence study outcomes",{"count":170,"type":22},718,[172],"PHASE4","The study aims to evaluate the appropriateness of initiating oral anticoagulation for stroke risk reduction in dialysis populations with atrial fibrillation. Specifically, the study will assess the overall safety, tolerability, and efficacy of initiating treatment with Warfarin in patients with end-stage renal disease on dialysis and atrial fibrillation.",[175,176,177,178],"Atrial Fibrillation and Flutter","Stroke","Major Bleed","End-stage Renal Disease","2026-05-17",{"date":181,"type":44},"2026-05-19",{"date":183,"type":44},"2019-10-09",{"date":185,"type":22},"2027-01",{"name":187,"class":51},"Nicholas Carlson",13,{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":196,"targetDuration":4,"studyType":23,"phases":198,"briefSummary":199,"conditions":200,"keywords":202,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":216,"locationsCount":52},"100637600","the-effect-of-intradialytic-eye-exercise-in-hemodialysis-patients-100637600","NCT07591714","The Effect of Intradialytic Eye Exercise in Hemodialysis Patients","The Effect of Intradialytic Eye Exercise on Physical Function, Balance, and Fall Risk in Hemodialysis Patients: A Randomized Pilot Trial","Inclusion Criteria\n\n* Adults ≥18 years receiving maintenance in-center hemodialysis\n* Clinically stable for brief seated intradialytic intervention\n* Able to understand and follow eye-exercise instructions\n* Able to provide informed consent\n* Able to sit upright independently during dialysis\n* Able to complete repeated outcome assessments\n* Able to communicate discomfort or adverse symptoms\n* Usual corrective lenses permitted if needed for visual clarity\n\nExclusion Criteria\n\n* Unstable cardiac conditions (e.g., unstable angina, recent myocardial infarction, decompensated heart failure, uncontrolled arrhythmia)\n* Active infection or acute medical illness\n* Hemodynamic instability\n* Significant cognitive or communication impairment preventing instruction-following\n* Severe uncorrected visual impairment or active ocular disease\n* Recent major ophthalmologic surgery\n* Severe musculoskeletal or neurologic limitations preventing participation or testing\n* Any condition deemed unsafe for intradialytic exercise by the treating physician or nephrologist",{"count":197,"type":22},30,[25],"This pilot randomized trial will evaluate whether a structured intradialytic eye-exercise program can be delivered safely and consistently during maintenance hemodialysis and whether it shows preliminary promise for improving physical function, balance, and fall-related concern. The study is needed because hemodialysis patients commonly experience impaired physical performance, reduced balance, and fear of falling, and these problems are associated with higher fall risk; at the same time, supervised exercise during dialysis is increasingly viewed as a practical way to reach this medically complex and often sedentary population. Eye-movement and gaze-stability training has also shown benefit for balance- and fall-related outcomes in older adults and stroke survivors, but its feasibility and potential value during dialysis sessions remain uncertain.",[30,201],"Hemodialysis Complication",[203,204,205,206,207,208,209],"Eye exercise","Gaze stabilization exercise","Home based exercise","Hemodialysis","Balance impairment","Fall risk","Physical function","2026-05-15",{"date":212,"type":44},"2026-05-18",{"date":214,"type":22},"2026-06",{"date":99,"type":22},{"name":217,"class":51},"Pardis Specialized Wellness Institute",{"id":219,"slug":220,"hasResults":12,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":23,"phases":226,"briefSummary":227,"conditions":228,"keywords":229,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":241},"100518566","an-extension-to-assess-the-effect-of-expanded-dialysis-on-patient-reported-symptoms-using-levil-100518566","NCT06032208","An Extension to Assess the Effect of Expanded Dialysis on Patient Reported Symptoms Using LEVIL","An Extension of an Interventional Study to Assess the Effect of Expanded Dialysis (HDx-Theranova) on Patient Reported Symptoms Using London Evaluation of Illness (LEVIL)","Inclusion Criteria:\n\n* Conventional thrice weekly HD schedule\n* Must be on chronic hemodialysis for at least 3 months\n* Age ≥18 years\n* Willing and able to give informed consent\n\nExclusion Criteria:\n\n* Active infection (may enroll once infection is cleared)\n* Patients receiving daily hemodialysis treatment\n* Patients currently receiving Hemodiafiltration (HDF), Hemofiltration (HF) or Isolated ultrafiltration (ISO UF) more than once in three months\n* Visual impairment\n* History of neurocognitive impairment\n* History of stroke (CVA)",{"count":144,"type":22},[25],"Investigators know that many patients who are on dialysis suffer from burden of unwanted symptoms, which can affect quality of life. The understanding and treatment of symptom burden by healthcare providers is limited and should be recognized as a high priority in the care of the dialysis population. In this study, the investigators will be assessing symptom burden using the London Evaluation of Illness \"LEVIL,\" an application based platform where patients self-report their symptoms with one to three hemodialysis treatments per week for 28 weeks. The investigators would like to compare the currently available dialyzer with a new dialyzer that is capable of removing solutes of higher molecular weight that may or may not cause patients to experience symptoms related to increased amounts of toxins in their blood.",[30],[206,230,231],"Large middle molecules","Theranova","2026-04-28",{"date":234,"type":44},"2026-05-04",{"date":236,"type":44},"2024-03-01",{"date":238,"type":22},"2026-12-31",{"name":240,"class":51},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",4,{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":249,"enrollmentInfo":250,"targetDuration":4,"studyType":23,"phases":252,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":265},"100530740","maturation-of-arteriovenous-fistula-with-automated-sonography-assessments-trial-100530740","NCT06190717","Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial","MAFASA","Inclusion Criteria:\n\n* Males or non-pregnant, non-breastfeeding females ≥ 18 years of age but \\\u003C 85 years of age at the time of informed consent.\n* Subject is able and willing to provide written informed consent prior to receiving any non-standard of care, protocol specific procedures.\n* Subject is willing and capable of complying with all required follow-up visits.\n* Subject and\u002For Care Team agree that the distance and transportation resources from the patient's home to the clinic are reasonable for study participation and compliance.\n* Subject has an estimated life expectancy \\> 18 months.\n* Subject is ambulatory (cane or walker are acceptable).\n* CKD Stage 5 (eGFR less than 10) or ESRD subjects presenting for upper arm autologous arteriovenous fistula creation that is not transposed for hemodialysis access.\n* Subjects who are currently on dialysis through a CVC or who imminently require dialysis (GFR \\\u003C10).\n* Vein diameter ≥ 2.5 mm at the antecubital fossa per vein mapping.\n* Artery diameter ≥ 2.5 mm per vein mapping.\n* Subject is not participating in another investigational clinical trial that has not met its primary end point. Participation in post-market registry is acceptable.\n\nExclusion Criteria:\n\n* CKD Stage 1-4 or subjects that do not require upper arm autologous arteriovenous fistula creation for hemodialysis access.\n* Subject has history of Steal Syndrome.\n* Subject who is immunocompromised or immunosuppressed.\n* Subject has had three previous failed AV fistulae for hemodialysis access.\n* Subjects expecting to undergo major surgery within 60 days from the EchoMark implantation.\n* Known or suspected active infection on the day of the index procedure.\n* Subjects who had infection(s) in the 30-day window prior to EchoMark placement to reduce the likelihood of partially treated infections that can seed the device and fistula.\n* Subjects with diagnosed bleeding disorder, thrombocytopenia (platelet count \\\u003C50,000), hypercoagulability, and history of recurrent deep vein thrombosis not related to AV access.\n* Subjects with active malignancy.\n* Subjects with a history of poor compliance with the dialysis protocol.\n* Subjects with a known or suspected allergy to any of the device materials.\n* Subjects with an existing fistula or graft.\n* Subjects who are anticipated to convert to peritoneal dialysis or undergo a transplant within 6 months.\n* Subjects who are pregnant, planning on becoming pregnant, or are breast feeding.","84 Years",{"count":251,"type":22},304,[25],"This is a prospective, multi-center, two-arm, randomized trial to quantify the performance of the EchoMark®\u002FEchoSure® System for AVF diagnostic ultrasound when used under a protocol of biweekly use for assessing fistula maturation and reducing time to Clinical Maturation.",[255,30],"Diabetes","2026-04-06",{"date":258,"type":44},"2026-04-13",{"date":260,"type":44},"2024-02-21",{"date":262,"type":22},"2027-02-01",{"name":264,"class":133},"Sonavex, Inc.",21,{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":23,"phases":274,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":52},"100609615","solv-multi-pass-hemodialysis-system-in-center-clinical-study-100609615","NCT07216885","Solv Multi-Pass Hemodialysis System In-Center Clinical Study","Inclusion Criteria:\n\n* Subjects able and willing to give Informed Consent and interested to participate in the study\n* Subject aged 18 years or older\n* Subjects meets one of the following three conditions:\n\n  * End stage renal disease (ESRD) patients who have been adequately treated with maintenance HD and deemed stable, according to the investigator, for at least three months\n  * Incident end stage renal disease (ESRD) patients who have been prescribed HD therapy\n  * Subjects on peritoneal dialysis who require conversion to hemodialysis, according to the investigator\n* Subjects who have adequate access, capable of providing a blood flow rate of at least 300 mL\u002Fmin\n* Subject understands the nature of the procedures and the requirements of the study protocol\n* Subject is willing and able to comply with the protocol requirements and return to the treatment center for all required treatments and clinical evaluations\n\nExclusion Criteria:\n\n* Subjects with baseline dry weight of ≤ 60 kg or ≥ 110 kg\n* Subjects with a documented history of non-compliance to scheduled hemodialysis sessions or clinic visits\n* Subjects who are pre-scheduled for a living kidney transplant within the next two months, who plan a change to peritoneal dialysis (PD) within the next two months or who require single needle dialysis therapy\n* Subjects with unstable electrolytes or acid base balance, in the opinion of the investigator\n* Subjects with any major surgery or major adverse cardiac event within 3 months of screening\n* Subjects with hemodynamic instability, defined as repeated hypo\u002Fhypertension, in the past 30 days from screening\n* Subjects with active or ongoing infection, in the opinion of the Investigator\n* Subjects with known Hepatitis B, C or HIV infection\n* Subject with documented coagulation disorders, active or bleeding risk or who is intolerant to heparin\n* Subjects who are currently participating or have previously participated in another interventional clinical trial in the past 4 weeks from screening\n* Subjects with any comorbidities possibly conflicting with the study purpose or procedures, in the opinion of the Investigator\n* Subjects who are pregnant or lactating or any patient with a childbearing potential who refuses to use medically acceptable means of contraception\n* Subjects with an active, malignant disease and whose life expectancy is \\\u003C 6 months, in the opinion of the investigator\n* Subjects with a hemoglobin \\\u003C 9 gm\u002Fdl in the past 30 days from screening\n* Subjects with significant intradialytic hypotension in 30 days from screening\n* Subjects with shock within 30 days from screening\n* Subjects with active seizures in the last 6 months from screening\n* Subjects with history of hemolytic anemia or thrombocytopenia\n* Subjects with vascular access dysfunction (switching ports (reverse lines or catheter replacement) in 30 days prior to screening, multiple tPA (tissue plasminogen activator) administrations) or patient who has had a thrombectomy procedure within 30 days prior to screening\n* Subjects with a documented history of congestive heart failure with symptoms consistent with NYHA Class III or IV, according to the investigator, or documented severe left ventricular dysfunction\n* Subjects with fluid overload due to intractable ascites secondary to liver cirrhosis\n* Subjects with active, life-threatening rheumatologic disease",{"count":273,"type":22},46,[25],"Solv In-Center clinical study is a pre-market, prospective, multicenter, single arm, open-label clinical study. The patient population will include patients with kidney failure or insufficiency requiring hemodialysis and\u002For ultrafiltration. Eligibility will be open to incident dialysis patients and patients currently receiving HD in an in-center environment. All vascular access types including AV-fistula, AV-graft, and tunneled hemodialysis catheters.",[30],"2026-03-26",{"date":279,"type":44},"2026-04-01",{"date":281,"type":44},"2026-01-13",{"date":283,"type":22},"2026-07",{"name":285,"class":133},"Mozarc Medical US LLC",{"id":287,"slug":288,"hasResults":12,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":23,"phases":296,"briefSummary":297,"conditions":298,"keywords":301,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":312},"100411237","post-market-surveillance-study-of-the-bd-wavelinq-endoavf-system-100411237","NCT04634916","Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System","A Prospective, Multi-Center Clinical Study of the BD® WavelinQ™ EndoAVF System for the Creation of Arteriovenous (AV) Fistula in Patients Requiring Dialysis","CONNECT-AV","Inclusion Criteria:\n\n1. Subject must be either male or non-pregnant female ≥ 18 years of age with an expected lifespan sufficient to allow for completion of all study procedures.\n2. Subject must voluntarily sign and date the Informed Consent Form (ICF) prior to collection of study data or performance of study procedures.\n3. Subject must be willing to comply with the protocol requirements, including clinical follow-up.\n4. Subjects who have established, non-reversible kidney failure, who are currently on dialysis at screening or are in immediate need (within 6 months of endoAVF creation) of dialysis.\n5. Target treatment vein diameter(s) for endoAVF creation ≥ 2.0 mm as measured via Duplex Ultrasound (DUS) or Venography.\n6. Target treatment artery diameter ≥ 2.0 mm as measured via Duplex Ultrasound (DUS) or Arteriogram.\n7. Subject has adequate collateral circulation to the hand, in the opinion of the Investigator.\n8. At least one superficial outflow vein diameter ≥ 2.5 mm and in communication with the target creation site via a proximal forearm perforating vein.\n\nExclusion Criteria:\n\n1. The subject is in a hypercoagulable state.\n2. The subject has known bleeding diathesis.\n3. The subject has insufficient cardiac output to support a native fistula in the opinion of the Investigator.\n4. Known history of active intravenous drug abuse.\n5. \"Planned\" major surgical procedure within 6 months following index procedure or major surgery within 30 days prior to index procedure.\n6. The subject has a known allergy or hypersensitivity to contrast media which cannot be adequately pre-medicated.\n7. The subject has known adverse effects to sedation and\u002For anesthesia which cannot be adequately pre-medicated.\n8. Evidence of active infection on the day of the index procedure (temperature of ≥ 38.0° Celsius and\u002F or WBC of ≥ 12,000 cells\u002F μL, if collected).\n9. The subject has another medical condition, which, in the opinion of the Investigator, may cause him\u002Fher to be non-compliant with the protocol, confound the data interpretation, or is associated with a life expectancy insufficient to allow for the completion of study procedures and follow-up.\n10. The subject is currently participating in an investigational drug or another device study that has not completed the study treatment or that clinically interferes with the study endpoints. Note: Studies requiring extended follow-up visits for products that were investigational, but have since become commercially available, are not considered investigational studies.\n11. The subject has central venous stenosis or central vein narrowing \\> 50% based on imaging on the same side as the planned endoAVF creation.\n12. Absence of a proximal forearm perforating vein feeding the target cannulation vein(s) from the target creation site via Duplex Ultrasound (DUS) or Venography.\n13. Occlusion or stenosis \\> 50% of target cannulation vein(s) such as cephalic, median cubital, basilic, etc. assessed via Duplex Ultrasound (DUS) or Venography.\n14. Significantly compromised venous or arterial flow in the treatment arm as determined by Investigator and Duplex Ultrasound (DUS) or Venography.\n15. Presence of significant calcification at the target endoAVF location that could potentially impact the effectiveness of endoAVF creation as determined by the Investigator.",{"count":295,"type":22},280,[25],"A prospective, single-arm, multi-center post-market surveillance study of the BD® WavelinQ™ EndoAVF System for the Creation of Arteriovenous (AV) Fistula in Patients Requiring Dialysis.",[299,178,300],"Kidney Disease, End-Stage","Arteriovenous Fistula",[302],"EndoAVF","2026-03-25",{"date":305,"type":44},"2026-03-27",{"date":307,"type":44},"2021-03-26",{"date":309,"type":22},"2027-09",{"name":311,"class":133},"C. R. Bard",17,{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":23,"phases":323,"briefSummary":325,"conditions":326,"keywords":327,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":339},"100362076","phase-3-efficacy-and-safety-of-xylocore-peritoneal-dialysis-solution-100362076","NCT03994471","Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.","A Study to EvaLuate the EffIcacy and Safety of XyloCore, a Glucose SparIng ExpeRimental Solution, for Peritoneal Dialysis","ELIXIR","INCLUSION CRITERIA:\n\n1. Age ≥18 years\n2. Diagnosed with ESRD and treated with CAPD in the last 3 months\n3. In stable clinical condition during the 3 months before screening as demonstrated by the absence of non-elective hospitalization and major cardiovascular events\n4. Have not experienced peritonitis episodes in the last 3 months\n5. In treatment with prescribed Extraneal (nocturnal exchange bag solution) for at least 1 month\n6. In treatment with 1, 2 or 3 diurnal exchange bag solution of prescribed Phisioneal (including Clear-Flex bag), Fixioneal, Dianeal or Dianeal Low Calcium (1.36%, 2.27% or 3.86% glucose), or Balance, Bicavera, Bicanova or Equibalance (1.25%, 2.3%, 4.5% glucose)\n7. Kt\u002FV urea measurement \\> 1.7 per week at Baseline Visit\n8. Followed\u002Ftreated by the participating clinical Center\u002FInvestigator in the last three months\n9. Understanding the nature of the study and providing their informed consent to participation.\n\nEXCLUSION CRITERIA:\n\n1. History of drug or alcohol abuse in the six months prior to entering the protocol\n2. In treatment with androgens\n3. Clinically significant abnormal liver function test (ɣ-GT \\> 4 times the upper normal limit)\n4. Acute infectious conditions (i.e.: pulmonary infection, acute hepatitis, high or low urinary tract infections, renal parenchymal infection, pericarditis, etc)\n5. Expected patient's survival shorter than the trial duration\n6. History of L-Carnitine therapy or use in the month prior to entering the protocol\n7. Have used any investigational drug in the 3 months prior to entering the protocol\n8. Female patients who are pregnant or breast-feeding.\n9. Female patients of childbearing age (less than 24 months after the last menstrual cycle) who do not use adequate contraception\n10. Patients affected by Primary Hyperoxaluria as per known medical therapy\n11. Patients with serum levels of uric acid \\> 7.2 mg\u002Fdl (male and postmenopausal women) or \\> 6.0 mg\u002Fdl (premenopausal women)\n12. Patients with a major cardiovascular event in the last 3 months\n13. Patients with advanced cardiac failure (NYHA 4)\n14. Hypersensitivity to any of the constituents of the study IMPs.\n15. Any contraindication to the prescribed Peritoneal Dialysis solutions (for long-dwell and short-dwell exchange) as per each product SmPC.\n16. Participants with medical history of oxalate or lactate abnormalities considered clinically significant by the investigator.\n17. History or evidence of any other medical, neurological or psychological condition that would expose the subject to an undue risk of a significant AE or interfere with study assessments during the course of the trial as determined by the clinical judgment of the investigator.",{"count":322,"type":22},170,[324],"PHASE3","Randomized, controlled, parallel groups, open-label, blinded end-point assessment, multicenter study, comparing the effects of a low glucose peritoneal dialysis solution, XyloCore, to glucose solutions (Physioneal, Fixioneal, Dianeal, Balance, Bicavera, Bicanova or Equibalance) only regimen, in patients with End-Stage Renal Disease (ESRD) receiving Continuous Ambulatory Peritoneal Dialysis (CAPD), over a 6-month study period.",[30],[328,329],"peritoneal dialysis","ESRD","2026-03-23",{"date":332,"type":44},"2026-03-24",{"date":334,"type":44},"2022-12-14",{"date":336,"type":22},"2027-04-28",{"name":338,"class":133},"Iperboreal Pharma Srl",41,{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":346,"enrollmentInfo":347,"targetDuration":4,"studyType":23,"phases":349,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":52},"100310460","phase-2-impact-of-envarsus-xr-on-kidney-biopsy-subclinical-rejection-and-blood-immunologic-profile-100310460","NCT03321656","Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile","Inclusion Criteria:\n\n* Fluent in English able to understand and provide informed consent.\n* End stage renal disease listed for primary solitary kidney transplant.\n* Willing to participate in the study and comply with study requirements as evidenced by signed IRB-approved informed consent.\n* Female who are of childbearing potential will be asked to use 2 different medically acceptable methods of contraception for the duration of the study and at least 1 year post-infusion.\n\nExclusion Criteria:\n\n* Previously undergone organ, tissue or cell transplant\n* Allergic to Tacrolimus or MMF (Cellcept)\n* Chronic use of blood thinners\n* Previous chronic use of glucocorticoids or other immunosuppression, or biologic immunomodulators (prescribed for the treatment of serious inflammatory disorders)\n* Significant or active infection\n* Diagnosed with HIV, Hepatitis B or C, Herpes simplex virus, Varicella-Zoster virus, Epstein-Barr virus\n* Have or have had cancer with in the past 3 years\n* Have taken part in another study that involved an investigational drug within the last 12 months.\n* Have a history of delayed or abnormal wound healing\n* Are pregnant or breastfeeding\n* Had a transfusion within the past 3 months\n* Have or plan to be receive a live vaccination (intranasal influenza measles, mumps, rubella, oral polio, yellow fever, varicella)\n* Are unable or unwilling to comply with study protocol or procedures.\n* Current use anticoagulation medication","75 Years",{"count":348,"type":22},78,[350,324],"PHASE2","This will be a single center, prospective, open-label, randomized, controlled trial comparing Envarsus XR® to twice-daily tacrolimus. The targeted population will be patients with end stage renal disease listed for primary solitary kidney transplant. Transplant Surgery is not part of the study.",[30],"2026-03-19",{"date":332,"type":44},{"date":356,"type":44},"2019-03-28",{"date":358,"type":22},"2027-03-31",{"name":360,"class":51},"Roberto Gedaly",{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":17,"minAge":369,"maxAge":370,"enrollmentInfo":371,"targetDuration":4,"studyType":23,"phases":373,"briefSummary":374,"conditions":375,"keywords":377,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":383,"leadSponsor":385,"locationsCount":52},"100562913","phase-1-bupropion-for-fatigue-in-end-stage-kidney-disease-patients-on-hemodialysis-100562913","NCT06609343","Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis","Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis (BRISK)","BRISK","Inclusion Criteria:\n\n1. Male and female ESKD patients between aged 25-74 yrs on maintenance in-center hemodialysis procedure 3 times\u002Fweek for ≥3 months with an arteriovenous fistula or graft.\n2. Blood hemoglobin of ≥10.0 g\u002FdL based on most recent routine laboratory profile.\n3. Dialysis adequacy measured with Kt\u002FV of ≥1.2\n4. Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n1. Currently on bupropion or hypersensitivity\u002F intolerance to bupropion by history and monoamine oxidase inhibitors.\n2. Diagnosis or history of eating disorders (bulimia or anorexia nervosa) and seizure.\n3. Pregnant, lactating, childbearing women\n4. History of post-acute COVID-19 syndrome\n5. Diagnosis of depression and\u002For on antidepressants and bipolar affective disorder\n6. Patient Health Questionnaire (PHQ)-9 score of ≥10\n7. Diagnosis of cognitive impairment including dementia\n8. Current participation in another interventional trial\n9. Scheduled for kidney transplantation in next 6 months\n10. Life expectancy \\\u003C6 months as judged by the attending nephrologist\u002Fprimary care physician.\n11. Current or history of substance abuse or dependency.","25 Years","74 Years",{"count":372,"type":22},16,[118,350],"Fatigue is the most common symptom reported by end-stage kidney disease patients on maintenance hemodialysis. Unfortunately, there currently is no medical management for this overwhelming feeling of tiredness. As a result, patients continue to suffer with poor quality of life and impaired daily activities. The purpose of this pilot trial is to find out if bupropion (a medicine commonly prescribed for stopping smoking, seasonal mood disorder, and depression) may help lessen fatigue in hemodialysis patients.\n\nIn this study, hemodialysis participants will receive bupropion tablet orally three times a week during routine dialysis procedure for consecutive 8 weeks. Study participants will complete a battery of questionnaires to self-report fatigue, cognition, and quality of life. The study team will collect biological specimens. All these procedures will be performed at the dialysis clinic during routine dialysis procedure.",[30,376],"Fatigue",[206,378],"Kidney dialysis","2026-03-10",{"date":381,"type":44},"2026-03-12",{"date":124,"type":22},{"date":384,"type":22},"2027-01-30",{"name":386,"class":51},"The University of Texas Health Science Center at San Antonio",{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":393,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":23,"phases":397,"briefSummary":398,"conditions":399,"keywords":401,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":415},"100495080","ckd-specific-telemonitoring-platform-to-minimize-adverse-outcomes-in-high-risk-ckd-patients-100495080","NCT05726526","CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients","A Pragmatic Randomized Controlled Trial of a CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients","VIEWER","Inclusion Criteria:\n\n* \\>18 years of age\n* Patient or primary caregiver can read and speak English\n* Patient or patients substitute decision maker is able to provide informed consent\n* Patient or primary care giver cognitively and physically capable and willing to use the VIEWER mobile application and perform self-measurements (i.e. weight, BP, etc.)\n* Have stage 5 CKD (2 measurements of eGFR \\\u003C15ml\u002Fmin\u002F1.73m2); eGFR will be calculated with the CKD-EPI equation, or have \\>40% chance of beginning dialysis in the next 2 years based on the Kidney Failure Risk Equation\n* Followed in a multidisciplinary CKD clinic\n\nExclusion Criteria:\n\n* Inability of self or caregiver assisted self-monitoring using VIEWER",{"count":396,"type":22},340,[25],"The main purpose of this trial is to determine whether the addition of the VIEWER virtual care platform to usual care will lead to a reduction in composite emergency department (ED) visits and\u002For hospitalizations\u002For increase the perceived safety of virtual care among patients and providers.",[400,30],"Chronic Kidney Disease Stage 5",[402,403,404,405],"telemonitoring","chronic kidney disease","suboptimal dialysis initiation","digital health","2026-03-05",{"date":408,"type":44},"2026-03-09",{"date":410,"type":44},"2022-06-30",{"date":412,"type":22},"2028-03-30",{"name":414,"class":51},"University of Manitoba",5,{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":420,"acronym":421,"eligibilityCriteria":422,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":423,"targetDuration":4,"studyType":23,"phases":425,"briefSummary":426,"conditions":427,"keywords":434,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":450,"locationsCount":452},"100516231","save-fistulas-the-selfwrap-assisted-arteriovenous-fistulas-study-100516231","NCT06001827","SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study","SAVE-FistulaS","Inclusion Criteria:\n\n* Age of at least 18 years\n* Referred for creation of a new AVF\n* Willing and able to comply with study requirements, communicate with the study team, and attend follow up visits over a period of 36 months\n\nExclusion Criteria:\n\n* Planned index procedure to revise or repair an existing fistula\n* Target artery inner diameter \\\u003C 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia\n* Target vein inner diameter \\\u003C 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia\n* Significant (at least 50%) stenosis at the target vein on the side of surgery (between the planned anastomosis site and the axillary vein), as diagnosed by preoperative ultrasound\n* Known central venous stenosis of at least 50% on the side of surgery\n* Presence of a stent or a stent graft within the access circuit\n* Known or suspected coagulation disorder that, in the opinion of the Investigator, puts too much risk on the patient for AVF creation\n* Known or suspected active infection at the time of surgery\n* Congestive heart failure NYHA class 4\n* Prior steal on the side of surgery;\n* Enrolled in another investigational drug, device, or biological study, or was previously enrolled in this study\n* Life expectancy less than 12 months\n* Expected to undergo kidney transplant surgery within 6 months of enrollment\n* Expected to undergo home hemodialysis\n* Females of childbearing potential (premenopausal and not surgically sterile) without documented current negative pregnancy test at screening\n* Presence of a comorbid condition that, in the opinion of the Investigator, may significantly confound the collection of safety and efficacy data in this study\n* Unwillingness or inability to give consent and\u002For comply with the study follow up schedule\n* Any health condition, which in the opinion of the Investigator, would interfere with the safety of the participant or the participant's ability to comply with the study.",{"count":424,"type":22},600,[25],"This is a prospective, randomized, multi-center clinical trial for chronic kidney disease (CKD) patients referred for creation of a new arteriovenous fistula (AVF) in order to assess the safety and effectiveness of SelfWrap, a bioabsorbable perivascular wrap.",[428,30,300,149,329,429,430,431,432,433],"Chronic Kidney Diseases","Vascular Access Complication","Renal Failure","Catheter Complications","Catheter Dysfunction","Renal Insufficiency",[435,436,437,438,439,440,206,441,442,30,300,443],"Vascular Surgery","Vascular Access","Nephrology","Bioabsorbable","Perivascular Wrap","External Support","Dialysis","Chronic Kidney Disease","AVF","2026-02-12",{"date":446,"type":44},"2026-02-17",{"date":448,"type":44},"2024-01-03",{"date":71,"type":22},{"name":451,"class":133},"VenoStent",28,{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":459,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":461,"enrollmentInfo":462,"targetDuration":4,"studyType":23,"phases":464,"briefSummary":465,"conditions":466,"keywords":468,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":479,"locationsCount":52},"100624662","autogenic-relaxation-and-murottal-therapy-in-hemodialysis-patients-100624662","NCT07412548","Autogenic Relaxation and Murottal Therapy in Hemodialysis Patients","The Effectiveness of Autogenic Relaxation and Surah Ar-Rahman Murottal Therapy on Anxiety, Sleep Quality, and Hemodynamic Parameters in Hemodialysis Patients","AR-MHD","Inclusion Criteria:\n\n1. Patients diagnosed with stage V chronic kidney disease.\n2. Undergoing scheduled hemodialysis at least twice a week for 6 weeks.\n3. Outpatients and aged 18-65 years.\n4. Muslim.\n5. Cooperative and able to communicate verbally.\n6. Willing to be a respondent by signing an informed consent form.\n\nExclusion Criteria:\n\n1. Having a severe heart condition or an unstable critical condition.\n2. Having a severe psychiatric disorder (schizophrenia, major depression).\n3. Having a cognitive, hearing, or speech disorder that impedes communication.\n4. Taking antidepressants, anxiolytics, or neuroleptics that may affect psychological measurement results.","65 Years",{"count":463,"type":22},76,[25],"This quasi-experimental study aims to evaluate the effect of combined autogenic relaxation and Surah Ar-Rahman murottal therapy on anxiety, sleep quality, and hemodynamic parameters in hemodialysis patients. A pretest-posttest control group design will be used involving 76 participants undergoing routine hemodialysis. Participants will be assigned to an intervention group receiving structured autogenic relaxation followed by murottal therapy and a control group receiving standard care with music listening. Anxiety, sleep quality, and hemodynamic parameters will be measured at baseline and after a 6-week intervention period. The findings are expected to support the use of non-pharmacological and spiritual-based interventions in improving psychological and physiological outcomes in hemodialysis patients.",[467,122,206],"Chronic Kidney Disease Stage V",[469,470,471,472,473],"Autogenic Relaxation","Murottal Therapy","Anxiety","Sleep Quality","Hemodynamics","2026-02-11",{"date":446,"type":44},{"date":477,"type":22},"2026-03-01",{"date":41,"type":22},{"name":480,"class":51},"Universitas Muhammadiyah Surakarta",{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":487,"eligibilityCriteria":488,"healthyVolunteers":112,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":489,"targetDuration":4,"studyType":23,"phases":491,"briefSummary":492,"conditions":493,"keywords":494,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":502,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":134},"100535846","impact-on-quality-of-life-of-symptoms-routine-e-monitoring-among-dialysis-patients-100535846","NCT06257134","Impact on Quality of Life of Symptoms Routine E-monitoring Among Dialysis Patients.","Impact on Quality of Life of Symptoms Routine E-monitoring Among Dialysis Patients, With Results Notification to Teams. A Cluster Randomised Controlled Trial Nested in a National Registry F-SWIFT (French Symptom Monitoring WIth Feedback Trial)","F-SWIFT","Inclusion Criteria:\n\nSymptom collection phase\n\nThe inclusion criteria for patients are as follows:\n\n* Individuals who have received full information on the organization of the research and who have not objected to their participation and to the use of their data.\n* Adults aged 18 and over\n* Patients with end-stage renal disease treated by dialysis in participating dialysis units\n* Patients able to answer questionnaires\n\nProcess evaluation phase\n\nThe inclusion criteria for healthcare professionals are as follows:\n\n* Individuals who have received full information on the organization of the research and who have not objected to their participation and to the use of their data.\n* Patients with end-stage renal disease treated by dialysis in participating dialysis units.\n* Doctors and nurses working in the dialysis unit taking part in the study.\n\nExclusion Criteria:\n\nThe non-inclusion criteria for patients are as follows:\n\n* Minors\n* Patients under legal protection, guardianship or curatorship\n* Patient not communicating or unable to give consent\n* Patient not being treated in a dialysis unit participating in the study\n* Patients being treated temporarily in a participating dialysis unit (respite care, vacationers, etc.)\n* Patient with cognitive disorders\n* Patient unable or unwilling to answer questionnaires\n\nThe non-inclusion criteria for healthcare professionals are as follows:\n\n* Non-voluntary healthcare professional\n* Healthcare professional not working in the participating facility",{"count":490,"type":22},2293,[25],"In France, end-stage renal disease (ESRD) affects almost 170 people per million inhabitants every year, and 92,500 people are treated by dialysis or kidney transplantation (0.14% of the French population).\n\nThe treatment of chronic renal failure is extremely costly: 4 billion euros in 2021, i.e. 2% of health insurance expenditure, and an annual cost of 42,000 euros per patient.\n\nThe health-related quality of life (HRQoL) of dialysis patients is low, with reports of patients at 40%-60% of full health. In France, there has been a significant decrease in physical (-15.4 points) and mental (-6.9 points) component scores compared with the general population. Dialysis patients often present severe or overwhelming symptoms, which contribute to this poor HRQoL. However, in nephrology, studies have focused on survival and laboratory biomarkers, and very few interventions have been aimed at improving what was a priority for patients, i.e. treating their symptoms and improving their HRQoL. Opportunities to intervene and improve symptom management and overall HRQoL may therefore have been missed.\n\nIgnoring patients' symptoms is an important omission. Of 28 randomized trials in primary care and oncology that measured the impact of communicating patient-reported outcomes to clinicians, 65% showed improved care processes and 47% improved health outcomes. The results of two recent randomized trials in oncology suggest that symptom monitoring can improve HRQoL and overall survival.\n\nThere is no evidence for dialysis patients, although therapeutic solutions are available in most cases.\n\nNephrology teams do not sufficiently recognize the prevalence, severity and negative effects of symptoms in their patients, and patients under-report their symptoms. With systematic symptom screening and automatic transmission of symptoms in the form of alerts, dialysis staff will be able to react and implement routine management to alleviate patients' symptoms.\n\nThe F-SWIFT study evaluates the hypothesis that regular symptom monitoring and feedback to hemodialysis patients and their dialysis staff improves patient HRQoL at 18 months.\n\nIn addition, the trial aims to determine whether electronic capture of patient-reported outcomes within a national dialysis patient registry is feasible and cost-effective, evaluated using consumption data from the Système National des données de Santé (SNDS) medico-administrative database.\n\nF-SWIFT is the French part of an international project (SWIFT) initiated in Australia in 2021: Australian New Zealand Clinical Trials Registry #ACTRN12620001061921. This French part is funded by Inserm's AAP MESSIDORE 2022.\n\nF-SWIFT is also the continuation of the pilot study n° 2021-A00776-35 accepted by the CPP EST II on 19\u002F10\u002F2021 and financed by the Agence de la Biomédecine (AOR 2021) in the RIPH3 category.",[30],[495,496,497,498,499,500,501],"Symptoms","Quality of life","IPOS-Renal","Dialysis units","ePROMS","Tablets","RedCAP",{"date":503,"type":44},"2026-02-13",{"date":505,"type":44},"2026-02-06",{"date":507,"type":22},"2026-12-15",{"name":509,"class":51},"Central Hospital, Nancy, France",{"id":511,"slug":512,"hasResults":12,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":516,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":518,"targetDuration":4,"studyType":23,"phases":520,"briefSummary":521,"conditions":522,"keywords":525,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":534,"locationsCount":536},"100412703","rheopheresis-as-adjuvant-treatment-of-calciphylaxis-100412703","NCT04654000","Rheopheresis as Adjuvant Treatment of Calciphylaxis","Efficacy of Rheopheresis as Adjuvant Treatment of Calciphylaxis in Hemodialysis Patients : a Prospective Randomized Controled Single-blind Trial","RHEO-CAL","Inclusion Criteria:\n\n* Calciphylaxis with at least one ulcerated or necrotizing lesion\n* End stage renal disease requiring hemodialysis\n* Weight superior to 30kg\n* Subject affiliated to or beneficiary of a social security system\n* Subject having signed written informed consent\n\nA patient with progressing calciphylaxis to ulcerate or necrosis despite conventional treatment may also be included.\n\nExclusion Criteria:\n\n* KARNOFSKY Performance Status Scale inferior to 30%\n* Life expectancy (independently of calciphylaxis) estimated \\\u003C 6 months according to a referring physician expert in hemodialysis\n* Uncontrolled infection (persistence of fever despite appropriate antibiotic therapy)\n* Common variable immunodeficiency\n* Albumin allergy\n* Contra-indication to stop anti-vitamin K treatment\n* Severe cognitive or psychiatric disorders, patients unable to give an informed consent or unwilling to participate in the study\n* Pregnancy or breastfeeding and all the other categories of people with special protection according to the French Code de la Santé Publique (CSP): patients under legal supervision, patients hospitalized without contentment, patients admitted in social or sanitary structures for care and not research, and patients in emergency situations.",{"count":519,"type":22},138,[25],"The investigators propose to set up a prospective randomized controlled trial to control the security and assess the efficacy of adjuvant treatment by rheopheresis in necrotizing-ulcered calciphylaxis in the hemodialysis population.",[523,30,524],"Metabolic Disorder","Rare Diseases",[526,527,206,528],"Calciphylaxis","Rheopheresis","Chronic kidney disease","2026-02-09",{"date":444,"type":44},{"date":532,"type":44},"2023-03-07",{"date":101,"type":22},{"name":535,"class":51},"University Hospital, Lille",29,{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":543,"eligibilityCriteria":544,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":545,"targetDuration":4,"studyType":23,"phases":547,"briefSummary":548,"conditions":549,"keywords":551,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":52},"100598536","hybrid-dissemination-study-of-a-digital-analog-intervention-to-increase-live-donor-kidney-transplantation-100598536","NCT07072767","Hybrid Dissemination Study of A Digital-Analog Intervention to Increase Live Donor Kidney Transplantation","Increasing Live Donor Kidney Transplantation Through Video-based Education and Mobile Communication","KIDNEYTIME+","Inclusion Criteria:\n\n* referred to the transplant center for a kidney transplant\n* aged 18 years and older\n* speaks English\n\nExclusion Criteria:\n\n* Previously exposed to any component of the intervention\n* Listed for a kidney transplant at another center (multilisted)\n* Seeking multiorgan transplantation",{"count":546,"type":22},430,[25],"The study is a 2-arm randomized controlled trial among patients referred for kidney transplant evaluation at a single transplant center to compare the effects of a digital-analog intervention to increase living-donor kidney transplant access (KidneyTIME+) with or without human guide . Following consent and baseline assessment, participants are randomized, stratified by self-reported race, with equal allocation to 2 treatment arms: the KidneyTIME+ intervention with or without human guide.",[122,428,39,550],"Living Kidney Donor",[552,553],"pilot randomized trial","behavioral intervention","2026-02-04",{"date":505,"type":44},{"date":557,"type":22},"2027-01-01",{"date":559,"type":22},"2030-07-01",{"name":561,"class":51},"State University of New York at Buffalo",{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":566,"acronym":567,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":17,"minAge":569,"maxAge":19,"enrollmentInfo":570,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":572,"conditions":573,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":52},"100620693","drug-interaction-potential-of-pro-inflammatory-conditions-100620693","NCT07360938","Drug Interaction Potential of Pro-Inflammatory Conditions","DIPPIC","Inclusion Criteria:\n\n* Diagnosed with a pro-inflammatory disease, including T2DM, IBD, and ESRD\n* Ability to provide written informed consent and HIPAA authorization\n\nExclusion Criteria:\n\n* Diagnosis or past medical history of non-IBD autoimmune disorder, including systemic lupus erythematosus, Sjogren's syndrome, multiple sclerosis, type 1 diabetes mellitus, Behcet's disease, and ankylosing spondylitis\n* Current infection requiring medical treatment (note: if a prospective patient's infection resolves, they can be re-screened for trial inclusion)\n* Concomitant treatment with systemic immunosuppressant drugs","12 Years",{"count":571,"type":22},150,"Pro-inflammatory cytokines, which are elevated in pro-inflammatory disease states (e.g., type II diabetes mellitus \\[T2DM\\], irritable bowel diseases \\[IBD\\], and end stage renal disease \\[ESRD\\]) have been shown to inhibit hepatic drug-metabolizing enzymes, including members of the cytochrome P450 (CYP) family, and drug transporters; resultantly, pro-inflammatory diseases have been demonstrated to increase the exposure and potential for adverse drug events with co-administered CYP and drug transporter substrates. However, the clinical relevance of pro-inflammatory disease-drug interactions has not been systematically evaluated. The long-term goal of this research is to establish clinical strategies to mitigate pro-inflammatory disease-drug interactions and associated adverse drug events. The specific objective of this study is to determine the clinical relevance of pro-inflammatory disease-drug interactions, including establishment of the effect of pro-inflammatory diseases on drug disposition throughout disease trajectories (i.e., determining the differential effects on drug disposition based on the severity of disease). Towards this objective, this study will investigate the extent of increases in inflammation in patients with varying severities of pro-inflammatory diseases and estimate the resulting effects on drug disposition. Cytokine\u002Fchemokine concentrations and immune cell profiles will be assayed from blood samples of adult and pediatric patients with differing severities of pro-inflammatory diseases, using established disease monitoring parameters (e.g., glycosylated hemoglobin \\[HbA1C\\] for T2DM, C-reactive protein \\[CRP\\] for IBD, proteinuria for ESRD). The effect of changes in inflammation during differing severities of these pro-inflammatory diseases on drug disposition will then be estimated using established pharmacokinetic modeling approaches (e.g., physiologically-based pharmacokinetic modeling \\[PBPK\\]).",[574,30,575],"Diabetes Mellitus, Type 2","Irritable Bowel Syndrome","2026-01-14",{"date":578,"type":44},"2026-01-22",{"date":580,"type":44},"2025-11-01",{"date":582,"type":22},"2030-12-31",{"name":584,"class":51},"Indiana University",{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":590,"acronym":591,"eligibilityCriteria":592,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":593,"targetDuration":4,"studyType":23,"phases":595,"briefSummary":596,"conditions":597,"keywords":599,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":606,"lastUpdatePostDateStruct":607,"startDateStruct":609,"completionDateStruct":611,"leadSponsor":613,"locationsCount":616},"100510810","phase-3-csp-2026---beta-blocker-dialyzability-on-cardiovascular-outcomes-100510810","NCT05931276","CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes","CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes (BRAVO)","BRAVO","Inclusion Criteria:\n\n* On hemodialysis\n* Received one of the following beta blockers through the VA pharmacy: metoprolol (succinate or tartrate), atenolol, labetalol, carvedilol, bisoprolol\n\nExclusion Criteria:\n\n* Impaired decision-making capacity\n* Patients not receiving carvedilol who have a history of asthma\n* known hypersensitivity to any component of either drug\n* Provider unwilling to sign a new medication order for a randomized patient\n* No surrogate consent will be allowed",{"count":594,"type":22},2540,[324],"The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.",[598,122],"End-Stage Kidney Disease",[441,600,601,602,603,604,605,206],"beta-Blockers, Adrenergic","Cardiovascular Diseases","Point of Care Research","Comparative Effectiveness Research","Metoprolol Succinate","Carvedilol","2026-01-07",{"date":608,"type":44},"2026-01-09",{"date":610,"type":44},"2024-05-22",{"date":612,"type":22},"2028-12-31",{"name":614,"class":615},"VA Office of Research and Development","FED",8,{"id":618,"slug":619,"hasResults":12,"nctId":620,"briefTitle":621,"officialTitle":622,"acronym":623,"eligibilityCriteria":624,"healthyVolunteers":12,"sex":17,"minAge":625,"maxAge":4,"enrollmentInfo":626,"targetDuration":628,"studyType":146,"phases":4,"briefSummary":629,"conditions":630,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":637,"completionDateStruct":639,"leadSponsor":641,"locationsCount":52},"100556185","cardio-renal-registry-100556185","NCT06521801","Cardio-Renal Registry","Barts Health Cardio-Renal Registry","BHCRR","Informed consent will not be sought for, as patients are automatically included onto a database that we will use for research purposes. No children will be included in this study. Vulnerable adults or those unable to give consent will be included in the study as well if they are referred to the Nephrology team.\n\nInclusion Criteria:\n\n1. Both male and female patients ≥16 years of age will be included\n2. All patients will be reviewed by the Nephrology team a the RLH with renal disease.\n\nExclusion Criteria:\n\n1\\. Patients \\\u003C16 years will not be included in this study.","16 Years",{"count":627,"type":22},60000,"12 Weeks","Cardiovascular disease is the leading cause of morbidity and mortality among patients with chronic kidney disease (CKD). Even after adjustment for known cardiovascular risk factors, including diabetes and hypertension, mortality risk progressively increases with worsening CKD. As glomerular filtration rate (GFR) declines the probability of developing coronary artery disease (CAD) increases linearly, and patients with GFR \\\u003C60 mL\u002Fmin\u002F1.73 m2 have 2-3-fold increased CV mortality risk, relative to patients without CKD. Management of CAD is complicated in CKD patients due to the likelihood of comorbid conditions and potential for side effects. Despite their high cardiovascular risk, ACS patients with renal dysfunction are less commonly treated with guideline-based medical therapy and are less frequently referred for coronary revascularisation. This observation, referred to as the \"treatment risk paradox,\" has been well described and may be explained by physicians' concerns regarding possible nonrenal side effects as well as renal toxicities. Furthermore, patients with severe CKD have traditionally been under-represented in most large cardiovascular clinical trials. Therefore, recommendations for both medical and revascularisation of CAD have relied heavily on extrapolation of results from the non-CKD population.\n\nThis data will add to that literature by assessing the characteristics and outcomes of patients with CAD and CKD. It will also identify and characterise predictors of outcomes, improve risk stratification and diagnostic evaluation.",[30,631,632,633,634,441],"Cardio-Renal Syndrome","Myocardial Infarction","Cerebrovascular Accident","Percutaneous Coronary Intervention","2026-01-05",{"date":606,"type":44},{"date":638,"type":44},"2024-08-01",{"date":640,"type":22},"2030-06-01",{"name":642,"class":51},"Queen Mary University of London",{"id":644,"slug":645,"hasResults":12,"nctId":646,"briefTitle":647,"officialTitle":648,"acronym":4,"eligibilityCriteria":649,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":650,"targetDuration":4,"studyType":23,"phases":652,"briefSummary":653,"conditions":654,"keywords":658,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":661,"startDateStruct":662,"completionDateStruct":664,"leadSponsor":665,"locationsCount":52},"100375064","blood-pressure-slopes-and-ultrafiltration-in-hemodialysis-patients-100375064","NCT04163614","Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients","Using Intradialytic Blood Pressure Slopes to Guide Ultrafiltration in Hemodialysis Patients","Inclusion Criteria:\n\n* Hemodialysis patient\n* Pre-dialysis systolic blood pressure greater than 140 mmHg averaged over 2 weeks OR post-dialysis systolic blood pressure greater than 130 mmHg averaged over 2 weeks\n\nExclusion Criteria:\n\n* HemoDialysis Vintage Less than 2 months\n* Pregnancy\n* Mean systolic blood pressure nadir \\\u003C95 mmHg in 2 weeks screening\n* Mean pre- or post-dialysis systolic blood pressure \\>180 mmHg\n* Mean pre to post-HD decrease in blood pressure \\>60 mmHg\n* Routine intradialytic clonidine use\n* Routine intradialytic midodrine use\n* Documented antihypertensive medication non-adherence\n* Mean ultrafiltration rate \\>13 mL\u002Fkg\u002Fhr during 2 week screening\n* For bioimpedance measurements only: amputation of a major extremity, presence of cardiac defibrillator or pacemaker, presence of a metallic implant (prosthetic joint)",{"count":651,"type":22},69,[25],"Kidney failure has been recognized as one of the most costly chronic conditions among United States Veterans. Approximately 13,000 Veterans develop kidney failure each year, and most require hemodialysis initiation. Hemodialysis patients suffer significantly increased risk of death and hospitalizations, and excessive body fluid is a major cause of this. While empiric aggressive fluid removal during dialysis is one approach to limit fluid overload, this can cause dangerous decreases in blood pressure during dialysis that independently contribute to the high death rate. In this study, I aim to test a new strategy that prescribes fluid removal based on a patient's recent blood pressure patterns during dialysis. This clinical trial will compare my strategy to standard care and assess the outcomes of overall blood pressure change between dialysis treatments in addition to the number of times the blood pressure becomes dangerously low during dialysis. Another aim is to determine how differences in the structure and function of the heart influence blood pressure during dialysis.",[30,655,656,657],"Hypertension","Extracellular Volume Overload","Intradialytic Hypotension",[30,655,659,657,660],"Extracellular Volume","Bioimpedance Spectroscopy",{"date":606,"type":44},{"date":663,"type":44},"2021-02-10",{"date":48,"type":22},{"name":614,"class":615},{"id":667,"slug":668,"hasResults":12,"nctId":669,"briefTitle":670,"officialTitle":671,"acronym":672,"eligibilityCriteria":673,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":674,"enrollmentInfo":675,"targetDuration":4,"studyType":23,"phases":676,"briefSummary":678,"conditions":679,"keywords":680,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":682,"lastUpdatePostDateStruct":683,"startDateStruct":685,"completionDateStruct":687,"leadSponsor":689,"locationsCount":52},"100493458","early-phase-1-oral-intradialytic-amino-acid-supplementation-to-vitalize-end-stage-kidney-disease-patients-on-hemodialysis-100493458","NCT05705414","Oral Intradialytic Amino Acid Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis","Oral Intradialytic Amino Acids Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis (OASIS)","OASIS","Inclusion Criteria:\n\n1. Male or Female\n2. Age 18-64 years\n3. Receiving 3 x weekly in clinic hemodialysis for at least 6 months\n\nExclusion Criteria:\n\n1. Hypersensitivity to amino acid(s) and\u002For any excipient\n2. Clinical documentation of COVID-19\n3. Concomitant intake of amino acids supplements\n4. Current use or abuse of alcohol, marijuana, narcotic, or other substances\n5. Heart failure receiving active management\n6. Malignant cancer receiving anticancer therapy\n7. Diagnosis of major depressive disorder receiving antidepressants\n8. Diagnosis of chronic liver disease\n9. Cerebrovascular disease with sequelae\n10. Upper limb amputation, osteoarthritis, or degenerative diseases of fingers, carpel tunnel syndrome in the non-fistula or graft hand preventing completion of hand grip strength test.","64 Years",{"count":452,"type":22},[677],"EARLY_PHASE1","The study will test and compare the efficacy of a single essential amino acid valine with a combination of essential amino acids (EAA) supplement on fatigue, frailty, and cognitive function in end-stage kidney disease (ESKD) patients undergoing hemodialysis (HD) treatment.",[30],[376,681,206],"End-stage kidney disease","2026-01-02",{"date":684,"type":44},"2026-01-06",{"date":686,"type":44},"2024-10-18",{"date":688,"type":22},"2026-12",{"name":386,"class":51}]